European Journal of Endocrinology Disclosure Policy
(last updated September 2015)

All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.

The following competing interests were disclosed:

**Tadej Battelino** – served on the advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic and Bayer Health Care. His institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamed. He also received honoraria for participating on the speaker’s bureaus of Eli Lilly, bayer, Novo Nordisk, Medtronic, Sanofi and Roch. Owns stocks in DreamMed.

**Kåre I. Birkeland** – has received payment from Novo Nordisk, Eli Lilly, sanofi-aventis, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer for participation at scientific meetings. Member of advisory boards, steering committees or data safety committees for Novo Nordisk, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen AS. Has received re-imbursements for chairing the Medical Advisory Committee of the Norwegian Diabetes Association. Member of The Norwegian Directorate of Health’s standing National Advisory Committee for Diabetes and in developing Norwegian guidelines for the treatment of diabetes.

**Cesar Luiz Boguszewski** – President of the International Committee of the Brazilian Society of Endocrinology and Metabolism. Member of the board of directors of the Pituitary Society, and of the Scientific & Educational programs core committee of The Endocrine Society. Active member of the Growth Hormone Research society. Speaker/consultant for NOVARTIS and IPSEN. Investigator of NOVARTIS, NOVO NORDISK and TEVA clinical trials.

**Ernesto Canalis** - has consulted for the National Institutes of Health, Eli Lilly and Amgen. Received honoraria and travel expenses for participation in a seminar at Regeneron Pharma; collaborated with scientists at Regeneron.

**Philippe Caron** – Has been a consultant for Ipsen lab, Merck Serono lab and Pierre Fabre lab. He has received personal fees from Pierre Fabre, Ipsen, Merck Serono, HAC, Novartis and Pfizer. Prof Caron is also on the advisory board for Ipsen.

**Martin Fassnacht** - member of The Endocrine Society Publication Core Committee.

**Ken Ho** - advisory board member of Novartis Ipsen and Versartis. Has also received funding from Novo Nordisk and Versartis.

**Gudmundur Johannsson** – has received lecture fees from Pfizer, NovoNordisk, Shire and Otsuka, and has been a consultant for Viopharma, Versatis and Astra Zeneca.

**Bente Langdahl** – on the advisory board of Amgen, Eli Lilly, MSD and UCB and has received research grants from Eli Lilly, Novartis, Novo Nordisk and Orkla Health.

**Juliane Leger** – Prof. Leger has received travel expenses from Novo Nordisk, Pfizer, Lilly, Mercks Serono and Sandoz.

**Antoine Tabarin** – occasional consultant and speaker for Ipsen Biotech, Novartis pharma and HRA Pharma.
The following editors reported no competing interests:
Maria Alevizaki
Marianne Andersen
Olaf Dekkers
Evanthia Diamanti-Kandarakis
Laura Fugazzola
Jose Moreno
Peter Nightingale
Johannes Romijn
Manuela Simoni
Jeremy Tomlinson
Jenny Tong

Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors’ declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.

This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).